Hexahydrocurcumin 是姜黄素的主要代谢产物之一,是一种选择性的口服活性COX-2抑制剂,对 COX-1 无活性。Hexahydrocurcumin 具有抗氧化,抗癌和抗炎的作用。
生物活性 | Hexahydrocurcumin is one of the major metabolites of curcumin and a selective, orally activeCOX-2inhibitor. Hexahydrocurcumin is inactive againstCOX-1. Hexahydrocurcumin has antioxidant, anticancer and anti-inflammatory activities[1][2]. |
IC50& Target[1] | |
体外研究 (In Vitro) | Hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) treatment significantly decreased the viability of HT-29 colon cancer cells in a time- and concentration-dependent. The respective IC50values for 24 and 48 h of Hexahydrocurcumin exposureare 77.05 and 56.95, respectively[1]. Hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) combined with 5-fluorouracil (5-FU; 5 μM) markedly reduces the COX-2 expression. The level of COX-1 is not altered[1]. Hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) combined with 5-fluorouracil (5-FU; 5 μM) markedly reduces the COX-2 protein. The level of COX-1 protein is not altered[1]. Hexahydrocurcumin (7-14 μM; 24 hours) attenuates lipopolysaccharide (LPS)-elicited increase of prostaglandin E2(PGE2) in murine macrophages (RAW 264.7) in a concentration-dependent manner[2].
Cell Viability Assay[1] Cell Line: | HT-29 cells | Concentration: | 0 μM, 5 μM, 10 μM, 25 μM | Incubation Time: | 24 hours or 48 hours | Result: | Significantly decreased the viability of HT-29 colon cancer cells. |
RT-PCR[1] Cell Line: | HT-29 cells | Concentration: | 25 μM | Incubation Time: | 24 hours | Result: | Combined with 5-fluorouracil (5-FU; 5 μM) markedly reduced the COX-2 expression. |
Western Blot Analysis[1] Cell Line: | HT-29 cells | Concentration: | 25 μM | Incubation Time: | 24 hours | Result: | Combined with 5-fluorouracil (5-FU; 5 μM) markedly reduced the COX-2 protein. |
|
体内研究 (In Vivo) | Hexahydrocurcumin (50 mg/kg; oral administration; daily; for 16 weeks; male Wistar rats) treatment significantly reduces the numbers of aberrant crypt foci (ACF) in colon cancer rats. Hexahydrocurcumin also markedly decreases COX-2 protein expression. The levels of COX-1 protein is not different from normal rats[3].
Animal Model: | Male Wistar rats (100-120 g) injected with dimethylhydrazine (DMH)[3] | Dosage: | 50 mg/kg | Administration: | Oral administration; daily; for 16 weeks | Result: | Significantly reduced the numbers of ACF in colon cancer rats. Also markedly decreased COX-2 protein expression. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | |
来源 | - Plants
- Zingiberaceae
- Curcuma longa
|
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 100 mg/mL(267.07 mM;Need ultrasonic) 配制储备液 1 mM | 2.6707 mL | 13.3536 mL | 26.7073 mL | 5 mM | 0.5341 mL | 2.6707 mL | 5.3415 mL | 10 mM | 0.2671 mL | 1.3354 mL | 2.6707 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (6.68 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.68 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (6.68 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.68 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (6.68 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.68 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|